BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 10637473)

  • 1. Involvement Value of FLT-3, c-Myc, STAT3, p27, and HOTAIR Gene Expression in Acute Myeloid Leukemia Patients: A Molecular Perspective to a Novel Leukemogenesis Mechanism.
    Shagerdi Esmaeli N; Asadi S; Bashash D; Salari S; Hamidpour M
    Int J Hematol Oncol Stem Cell Res; 2023 Jul; 17(3):145-155. PubMed ID: 37817968
    [No Abstract]   [Full Text] [Related]  

  • 2. p27kip1: a target for tumor therapies?
    Nickeleit I; Zender S; Kossatz U; Malek NP
    Cell Div; 2007 May; 2():13. PubMed ID: 17488529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircRNAs as New Therapeutic Entities and Tools for Target Identification in Acute Myeloid Leukemia.
    Nopora A; Weidle UH
    Cancer Genomics Proteomics; 2024; 21(2):118-136. PubMed ID: 38423599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon.
    Ghelli Luserna di Rorà A; Jandoubi M; Martinelli G; Simonetti G
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors in malignant hematopoiesis.
    Schirripa A; Sexl V; Kollmann K
    Front Oncol; 2022; 12():916682. PubMed ID: 36033505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA circCRKL inhibits the proliferation of acute myeloid leukemia cells via the miR-196a-5p/miR-196b-5p/p27 axis.
    Liu W; Cheng F
    Bioengineered; 2021 Dec; 12(1):7704-7713. PubMed ID: 34617876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
    Kodigepalli KM; Bonifati S; Tirumuru N; Wu L
    Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27
    Peschel I; Podmirseg SR; Taschler M; Duyster J; Götze KS; Sill H; Nachbaur D; Jäkel H; Hengst L
    Haematologica; 2017 Aug; 102(8):1378-1389. PubMed ID: 28522571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cap-Independent Translation in Hematological Malignancies.
    Horvilleur E; Wilson LA; Bastide A; Piñeiro D; Pöyry TA; Willis AE
    Front Oncol; 2015; 5():293. PubMed ID: 26734574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.
    Brenner AK; Reikvam H; Lavecchia A; Bruserud Ø
    Molecules; 2014 Nov; 19(11):18414-47. PubMed ID: 25397735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell cycle control in acute myeloid leukemia.
    Schnerch D; Yalcintepe J; Schmidts A; Becker H; Follo M; Engelhardt M; Wäsch R
    Am J Cancer Res; 2012; 2(5):508-28. PubMed ID: 22957304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia.
    Haferlach C; Bacher U; Kohlmann A; Schindela S; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Jun; 96(6):829-36. PubMed ID: 21422114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
    Nakamura S; Yamashita M; Yokota D; Hirano I; Ono T; Fujie M; Shibata K; Niimi T; Suyama T; Maddali K; Asai K; Yamashita J; Iguchi Y; Ohnishi K
    Invest New Drugs; 2010 Aug; 28(4):381-91. PubMed ID: 19436953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis.
    Martins CP; Berns A
    EMBO J; 2002 Jul; 21(14):3739-48. PubMed ID: 12110586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
    Milella M; Kornblau SM; Estrov Z; Carter BZ; Lapillonne H; Harris D; Konopleva M; Zhao S; Estey E; Andreeff M
    J Clin Invest; 2001 Sep; 108(6):851-9. PubMed ID: 11560954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia.
    Yokozawa T; Towatari M; Iida H; Takeyama K; Tanimoto M; Kiyoi H; Motoji T; Asou N; Saito K; Takeuchi M; Kobayashi Y; Miyawaki S; Kodera Y; Ohno R; Saito H; Naoe T
    Leukemia; 2000 Jan; 14(1):28-33. PubMed ID: 10637473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic potential of bone marrow cyclin E and P27, in Egyptian patients with acute myeloid leukemia.
    Abdel Alim A; Youssef SR; Farouk HM
    Egypt J Immunol; 2010; 17(1):9-18. PubMed ID: 22053605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia.
    Min YH; Cheong JW; Kim JY; Eom JI; Lee ST; Hahn JS; Ko YW; Lee MH
    Cancer Res; 2004 Aug; 64(15):5225-31. PubMed ID: 15289327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.
    Cote RJ; Shi Y; Groshen S; Feng AC; Cordon-Cardo C; Skinner D; Lieskovosky G
    J Natl Cancer Inst; 1998 Jun; 90(12):916-20. PubMed ID: 9637141
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.